CAS: 147539-41-1; Tert-Butyl 4-(Methylamino)Piperidine-1-Carboxylate

该化合物是有机合成的多用途中间体,对制药和农用化学应用特别有用. 其受保护的矿物质组在反应过程中增强了稳定性,而甲基氨基替代组则为进一步功能化提供了一个反应场所. 化合物的管状丁基磺酸是生物活性分子中常见的动脉素,有助于建立药剂. 其高纯度和定义明确的结构确保了合成途径的再生性. 在温和酸条件下,可有选择地保护乙基氧基(Boc)组,在多步合成中提供灵活性. 这种化合物因其平衡的再活动性和保护性群体兼容性,在开发含有地雷的目标分子方面特别有利.

结构式图片

相似化合物

221352-86-9 7006-50-0 73874-95-0

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号197727-57-4 4-[乙酰基(甲基)氨基]哌啶... | CAS号76167-62-9 4-(N-甲基-N-苄基)氨基哌啶 | CAS号64951-39-9 N-METHYL-N-4-PI... | CAS号70724-74-2 N-甲基-N-(哌啶-4-基)甲基磺酰胺

合成工艺路线路线简述

    4-(N-(2-Phenylethyl)Amino)-1-(Tert-Butoxycarbonyl)Piperidine置于palladium Hydroxide On Carbon 氢气体系中,用 甲醇 用作溶剂,化学反应生成1-叔丁氧羰基-4-甲氨基哌啶
    参考文献:Ep1847535
    标题:Ep1847535

    海关参考信息

    专利信息


    专利号:US-9458111-B2
    优先权日:2010-07-29
    标题:Process for the synthesis of substituted urea compounds
    发明人:LEARMONTH DAVID ALEXANDER; BROADBELT BRIAN; WAHNON JORGE BRUNO REIS
    权利人:LEARMONTH DAVID ALEXANDER; BROADBELT BRIAN; WAHNON JORGE BRUNO REIS; BIAL—PORTELA & CA S A
    摘要:A process for preparing a substitute urea of Formula (II) or Formula (I), or a pharmaceutically acceptable salt or ester thereof: n nthe process comprising the reaction of a carbamate of Formula (II′): Formula (I′):n n nwith a primary or secondary amine of the formula R1R2NH, wherein ring A, and R1, R2, R5, V, W, X, Y and Z are as defined herein.

    专利号:US-8933227-B2
    优先权日:2009-08-14
    标题 :Selective synthesis of functionalized pyrimidines
    发明人:LINZ GUENTER; KRAEMER GERD; KUSSEROW SABRINA; SCHNAUBELT JUERGEN
    权利人:LINZ GUENTER; KRAEMER GERD; KUSSEROW SABRINA; SCHNAUBELT JUERGEN; BOEHRINGER INGELHEIM INT
    摘要:The present invention relates to a process for making 2,4-differentiated 5-trifluoromethyl pyrimidines and 2-amino-5-trifluoromethyl-pyrimidine derivatives, which compounds are useful in the preparation of pharmacologically active compounds.

    专利号:US-11787803-B2
    优先权日:2017-09-15
    标 题 :Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
    发明人:SCHILLER SHAWN E R; HERBERTZ TORSTEN; LI HONGBIN; GRAVES BRADFORD; MISCHKE STEVEN; WEST ANGELA V; DOWNING JENNIFER R; ERICSSON ANNA
    权利人:FORMA THERAPEUTICS INC
    摘要:The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

    专利号:US-2013123493-A1
    优先权日:2010-07-29
    标题 :Process for the synthesis of substituted urea compounds

    专利号:US-2011190499-A1
    优先权日:2009-08-14
    标题 :Selective synthesis of functionalized pyrimidines

    专利号:EP-2606035-B1
    优先权日:2010-07-29
    标题:Proces for the synthesis of substituted urea compounds
    天津瑞发化工科技发展有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.refinechemicals.com
    企业联系电话:+86-22-87899130👤
    📞天津瑞发化工科技发展有限公司 ⚠️参考联系方式
    联系人:张先生
    电话:+86-22-87899130
    手机:18114031056
    传真:+86-22-87899129
    邮箱:sales@refinechemicals.com
    通信地址: 天津市科研西路12号
    邮编: 300192
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:天津市科研西路12号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海易信生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.bioyeexin.com
    电话: 021-54176788 13671761800👤
    📞上海易信生物科技有限公司 ⚠️参考联系方式

    销售电话:021-54176788 13671761800
    邮箱:sales@bioyeexin.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海市水清路999弄61号602室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1126/science.abo7201
    摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知